Vitamin D for Lymphoma
Trial Summary
What is the purpose of this trial?
This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.
Do I need to stop my current medications for the Vitamin D for Lymphoma trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, you can participate in other therapies for your disease as long as they do not involve vitamin D.
What data supports the effectiveness of the drug Cholecalciferol (Vitamin D3) for treating lymphoma?
Is Vitamin D3 safe for humans?
How does the drug Cholecalciferol differ from other treatments for lymphoma?
Cholecalciferol (Vitamin D3) is unique because it focuses on addressing vitamin D deficiency, which has been linked to poorer survival outcomes in certain types of lymphoma, like extranodal natural killer/T-cell lymphoma. Unlike traditional chemotherapy or radiation, this drug aims to improve patient outcomes by potentially enhancing vitamin D levels, which may have protective effects against lymphoma.247910
Research Team
Thomas E. Witzig, M.D.
Principal Investigator
Mayo Clinic
Eligibility Criteria
This trial is for newly diagnosed patients with aggressive lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma who can swallow capsules, are willing to return for follow-up and provide blood samples. They must have normal serum calcium levels and confirmed vitamin D insufficiency.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Vitamin D insufficient patients receive cholecalciferol orally once weekly for 12 weeks and then once monthly for a total of 36 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cholecalciferol (Vitamin Supplement)
Cholecalciferol is already approved in Canada, Japan, China, Switzerland for the following indications:
- Prevention and treatment of vitamin D deficiency
- Osteoporosis prevention
- Rickets prevention
- Prevention and treatment of vitamin D deficiency
- Osteoporosis prevention
- Rickets prevention
- Prevention and treatment of vitamin D deficiency
- Osteoporosis prevention
- Rickets prevention
- Prevention and treatment of vitamin D deficiency
- Osteoporosis prevention
- Rickets prevention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Dr. Gianrico Farrugia
Mayo Clinic
Chief Executive Officer since 2019
MD from University of Malta Medical School
Dr. Richard Afable
Mayo Clinic
Chief Medical Officer
MD from Loyola Stritch School of Medicine
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School